Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition

Abstract Hepatocellular carcinoma (HCC) is a widely prevalent type of primary liver cancer. However, strategies for pretumor intervention are still limited. In this study, a liver‐specific Zbtb7b knockout mouse model was used to evaluate the role of Zbtb7b in metabolic dysfunction‐associated steatot...

Full description

Saved in:
Bibliographic Details
Main Authors: Yinglin Han, Kaimin Wu, Xin Peng, Yinkun Fu, Wenyan Li, Jing Ma, He Jiang, Xu‐Yun Zhao
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Physiological Reports
Subjects:
Online Access:https://doi.org/10.14814/phy2.70160
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846099662814052352
author Yinglin Han
Kaimin Wu
Xin Peng
Yinkun Fu
Wenyan Li
Jing Ma
He Jiang
Xu‐Yun Zhao
author_facet Yinglin Han
Kaimin Wu
Xin Peng
Yinkun Fu
Wenyan Li
Jing Ma
He Jiang
Xu‐Yun Zhao
author_sort Yinglin Han
collection DOAJ
description Abstract Hepatocellular carcinoma (HCC) is a widely prevalent type of primary liver cancer. However, strategies for pretumor intervention are still limited. In this study, a liver‐specific Zbtb7b knockout mouse model was used to evaluate the role of Zbtb7b in metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related HCC development. We revealed that Zbtb7b was compensatively increased and restricted lipid deposition in the liver during MASLD progression, which protects against MASLD‐related HCC initiation. Mechanistically, Zbtb7b suppresses the expression of the long noncoding RNA H19 to attenuate hepatic de novo lipogenesis and increase fatty acid oxidation, thereby preventing lipid accumulation in hepatocytes. As a result, the proliferation and migration abilities of HCC cells are reduced. Overall, we demonstrated that Zbtb7b serves as a tumor suppressor at an early stage of HCC, thus providing a promising target for the treatment of HCC at a premalignant stage.
format Article
id doaj-art-9d3196648a8b4f0b9bfca5c300b7ad74
institution Kabale University
issn 2051-817X
language English
publishDate 2024-12-01
publisher Wiley
record_format Article
series Physiological Reports
spelling doaj-art-9d3196648a8b4f0b9bfca5c300b7ad742024-12-31T08:52:31ZengWileyPhysiological Reports2051-817X2024-12-011224n/an/a10.14814/phy2.70160Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid depositionYinglin Han0Kaimin Wu1Xin Peng2Yinkun Fu3Wenyan Li4Jing Ma5He Jiang6Xu‐Yun Zhao7Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Ministry of Education Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Endocrinology and Metabolism, Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaLiver Cancer Institute, Zhongshan Hospital Fudan University, Shanghai Medical College Shanghai ChinaDepartment of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education Shanghai Jiao Tong University School of Medicine Shanghai ChinaAbstract Hepatocellular carcinoma (HCC) is a widely prevalent type of primary liver cancer. However, strategies for pretumor intervention are still limited. In this study, a liver‐specific Zbtb7b knockout mouse model was used to evaluate the role of Zbtb7b in metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related HCC development. We revealed that Zbtb7b was compensatively increased and restricted lipid deposition in the liver during MASLD progression, which protects against MASLD‐related HCC initiation. Mechanistically, Zbtb7b suppresses the expression of the long noncoding RNA H19 to attenuate hepatic de novo lipogenesis and increase fatty acid oxidation, thereby preventing lipid accumulation in hepatocytes. As a result, the proliferation and migration abilities of HCC cells are reduced. Overall, we demonstrated that Zbtb7b serves as a tumor suppressor at an early stage of HCC, thus providing a promising target for the treatment of HCC at a premalignant stage.https://doi.org/10.14814/phy2.70160de novo lipogenesisfatty acid oxidationH19hepatocellular carcinomametabolic dysfunction‐associated steatotic liver diseaseZbtb7b
spellingShingle Yinglin Han
Kaimin Wu
Xin Peng
Yinkun Fu
Wenyan Li
Jing Ma
He Jiang
Xu‐Yun Zhao
Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition
Physiological Reports
de novo lipogenesis
fatty acid oxidation
H19
hepatocellular carcinoma
metabolic dysfunction‐associated steatotic liver disease
Zbtb7b
title Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition
title_full Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition
title_fullStr Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition
title_full_unstemmed Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition
title_short Zbtb7b defines a compensatory mechanism in MASLD‐related HCC progression by suppressing H19‐mediated hepatic lipid deposition
title_sort zbtb7b defines a compensatory mechanism in masld related hcc progression by suppressing h19 mediated hepatic lipid deposition
topic de novo lipogenesis
fatty acid oxidation
H19
hepatocellular carcinoma
metabolic dysfunction‐associated steatotic liver disease
Zbtb7b
url https://doi.org/10.14814/phy2.70160
work_keys_str_mv AT yinglinhan zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT kaiminwu zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT xinpeng zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT yinkunfu zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT wenyanli zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT jingma zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT hejiang zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition
AT xuyunzhao zbtb7bdefinesacompensatorymechanisminmasldrelatedhccprogressionbysuppressingh19mediatedhepaticlipiddeposition